ArticleJPGN reports2026
A retrospective cohort study evaluating the growth and clinical outcomes of preterm and term infants with cystic fibrosis during the first 11 years of life.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Infants with cystic fibrosis (iwCF) have lower birth weights than others. That influences nutritional and pulmonary outcomes. It was reported that 86.0% of iwCF were born full-term and 14.0% preterm. Data on the role of gestational age in growth and clinical outcomes of people with cystic fibrosis (pwCF) is limited. Objectives of this study are to assess the impact of gestational age on the growth and clinical outcomes of pwCF at 2 and 11 years of age and pulmonary function at 6 and 11 years of age. Methods: This is a retrospective, single-center, cross-sectional study, conducted between 2008 and 2024, for pwCF at Michigan Medicine. Results: A total of 170 pwCF were enrolled, 21 were premature, and 149 were full term. There was no statistical significance between the two groups in hospitalization rate, pancreatic enzyme replacement therapy, Dornase alfa use, Pseudomonas aeruginosa colonization, and cystic fibrosis transmembrane conductance regulator modulators use. There was a statistically significant difference in Vitamin K supplement, Ursodiol, and proton pump inhibitors use, with all used more in the premature group. There was no statistical significance of weight for length (WFL) at birth. At 2 years of age, there was a statistically significant difference in WFL and in body mass index between the two groups at 11 years of age. Conclusion: Our study demonstrated a statistically significant difference in preterm WFL percentile compared to term pwCF at 2 years of age, with preterm pwCF having a lower average WFL percentile (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.